Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/CT095020010-e_fig1_carousel.jpg)
Dermatologic Toxicity in a Patient Receiving Liposomal Doxorubicin
- Author:
- Kristen N. Richards, MD
- Rebecca L. Stone, MD
- Rashid M. Rashid, MD, PhD
Liposomal doxorubicin hydrochloride is an anthracycline topoisomerase inhibitor indicated for ovarian cancer, AIDS-related Kaposi sarcoma, and...